ProStrakan Group, a specialty pharmaceutical company, has announced the US launch of Sancuso, its novel, patent protected, transdermal patch for the prevention of chemotherapy-induced nausea and vomiting in patients receiving chemotherapy.

 

ProStrakan Group is also working with regulatory authorities to bring Sancuso to market in Europe.  Sancuso was previously approved by the FDA as the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately or highly nausea-inducing chemotherapy regimen.

Sancuso is a transdermal system, or skin patch, that delivers granisetron, its active component and an established preventor of nausea and vomiting, through a thin layer of adhesive that attaches the patch to the skin on the upper outer arm.

Wilson Totten, CEO of ProStrakan, said: "As a company dedicated to the needs of the patients, we are thrilled to be launching our first product in the US. The ability to successfully bring Sancuso to the oncology community opens doors for us to introduce other supportive oncology care products, particularly those designed for easier patient use."